Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2019

View Archived Issues

An inclusive look at the microbiome

NGM reports promising interim results from ongoing phase II study of aldafermin in NASH

Xoc Pharmaceuticals launches phase I study of XC101-D13H

New mouse model of diabetic cystopathy described

Discovery of novel potent fully human FVIII mimetic BiAb, KY-1049

Selepressin does not improve vasopressor- and ventilator-free days in patients with septic shock

Preliminary data presented from phase I/II ASPIRO study of AT-132

MinL4.0 RSV: a synthetic, live-attenuated vaccine against respiratory syncytial virus

MTPS-9579A dose-dependently inactivates airway tryptase for the treatment of asthma

FDA approves Wilate for hemophilia A

Tezepelumab reduces activation of matrix remodeling and inflammatory pathways

Scenesse wins approval in U.S. for erythropoietic protoporphyria

GSK and Lyell Immunopharma collaborate to improve cell therapies for cancer

Faron receives DMC feedback for phase I/II MATINS trial of Clevegen

U.S. researchers patent ATR kinase inhibitors

University of California discloses new VLA-2 antagonists

Pfizer identifies antibacterial agents

Hinova Pharmaceuticals details compounds for cancer

New ALK kinase inhibitors revealed in University of Michigan patent

New CRISPR-Cas9 variant may boost gene-editing precision

AZD-4205 begins phase I/II study in Korea for peripheral T-cell lymphoma

Incyte initiates phase I/II study of INCB-001158 with daratumumab in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...